Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi[®] during the second quarter 2024, in conjunction with their partner Biogen’s second quarter report. In total, sales of JPY 6.3 billion were recorded in the period, an increase of more than 120% compared to the previous quarter (Q1 2024: JPY 2.8 billion), resulting in a royalty to BioArctic amounting to approximately SEK 43 million.Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and